Company Overview and News
* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing Source text: (bit.ly/2AiGwl1) Further company coverage: (26-1)
* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage: (26-0)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)
Good day, ladies and gentlemen and welcome to the Cellectar Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (43-0)
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)
* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates (43-0)
Good morning, and welcome to Onconova’s Second Quarter 2017 Earnings Call and Webcast. At this time, all participants have been placed on listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. [Operator instructions]
* Onconova Therapeutics announces establishment of collaborative research and clinical programs evaluating rigosertib in pediatric “rasopathies”
Good morning, ladies and gentlemen and welcome to the Onconova Therapeutics Full-Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
When a person or group of persons acquires beneficial ownership of more than 5% of a company’s equity securities, they are required to file a Schedule 13D or 13G with the SEC.
* Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics Inc as of April 21 - sec filing Source text : bit.ly/2oQ05LT Further company coverage: (0-1)
* Onconova Therapeutics Inc - intends to use net proceeds from offering to support development of rigosertib for treatment in higher risk mds Source text for Eikon: Further company coverage: (0-1)
• General Communication, Inc.’s shares advanced 62.4% after Liberty Interactive Corporation (LVNTA - Free Report) revealed plans to acquire General Communication for $1.12 billion • Shares of Acuity Brands, Inc. (AYI - Free Report) fell 2.2% after reporting second-quarter fiscal 2017 adjusted earnings of $1.65 per share, missing the Zacks Consensus Estimate of $1.70 • RedHill Biopharma Ltd’s (RDHL - Free Report) shares advanced 4.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton